Form 4: Teva Pharmaceutical Industries Executive Sells Shares to Cover Tax Obligations

David R. McAvoy, EVP and Chief Legal Officer of Teva Pharmaceutical Industries, sold shares to cover tax withholding obligations related to vesting restricted share units.

Summary

• David R. McAvoy, EVP and Chief Legal Officer of Teva Pharmaceutical Industries, filed a Form 4 detailing changes in beneficial ownership.
• On March 4, 2025, McAvoy exercised 16,741 restricted share units, receiving ordinary shares.
• Also on March 4, 2025, McAvoy sold 3,150 ordinary shares at a weighted average price of $15.7346 per share.
• On March 5, 2025, McAvoy sold an additional 1,677 ordinary shares at a weighted average price of $15.9132 per share.
• These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 15, 2024.
• The sales were to cover tax withholding obligations related to the vesting of restricted share units.
• Following these transactions, McAvoy directly owns 11,914 ordinary shares and 50,223 restricted share units.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing executive share transactions. It doesn't convey any particularly positive or negative sentiment about the company's performance or prospects.

Future Outlook

The reporting person will have 16,741 restricted share units vesting on each of March 4, 2026, March 4, 2027 and March 4, 2028.

Industry Context

Executive share sales are a common occurrence, often related to compensation and tax planning. The use of a 10b5-1 plan suggests the sales were pre-planned and not based on insider information.

Comparison to Industry Standards

• Executive compensation packages often include restricted stock units that vest over time.
• Selling shares to cover tax obligations upon vesting is a standard practice among executives in publicly traded companies.
• Rule 10b5-1 trading plans are widely used by corporate insiders to schedule stock sales in advance, ensuring compliance with insider trading laws.
• Comparing McAvoy's transactions to those of executives at similar pharmaceutical companies (e.g., Pfizer, Novartis) would provide further context, but that data is not available in this document.

Stakeholder Impact

• The share sales by an executive could have a minor negative impact on shareholder sentiment, but the pre-planned nature of the sales mitigates this concern.
• The impact on employees, customers, suppliers, and creditors is likely negligible.

Key Dates

Keywords

Form 4, Teva Pharmaceutical Industries, David R. McAvoy, Share Sale, Restricted Share Units, Beneficial Ownership, Rule 10b5-1, Tax Withholding